Research ExplorerPublicationsDoes gamma-glutamyltransferase correlate with liver tumor bu...

Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?

Standard

Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors? / Schmidt, Benjamin Christopher; Leiderer, Miriam Theresa; Amin, Tania; Viol, Fabrice; Huber, Samuel; Henes, Frank Oliver; Schrader, Jörg.

In: ENDOCRINE, Vol. 83, No. 2, 02.2024, p. 511-518.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schmidt, BC, Leiderer, MT, Amin, T, Viol, F, Huber, S, Henes, FO & Schrader, J 2024, 'Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?', ENDOCRINE, vol. 83, no. 2, pp. 511-518. https://doi.org/10.1007/s12020-023-03545-x

APA

Schmidt, B. C., Leiderer, M. T., Amin, T., Viol, F., Huber, S., Henes, F. O., & Schrader, J. (2024). Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors? ENDOCRINE, 83(2), 511-518. https://doi.org/10.1007/s12020-023-03545-x

Vancouver

Schmidt BC, Leiderer MT, Amin T, Viol F, Huber S, Henes FO et al. Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors? ENDOCRINE. 2024 Feb;83(2):511-518. https://doi.org/10.1007/s12020-023-03545-x

Bibtex

@article{12fe8a92c426473ba69430042365c410,
title = "Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?",
abstract = "PURPOSE: In patients with neuroendocrine tumors (NETs) and liver metastases, increased gamma-glutamyltransferase (GGT) is commonly assumed as an indicator for progressive disease. To date, however, empirical data are lacking. This study aimed to investigate associations between GGT and liver tumor burden. In longitudinal analyses, associations of GGT and radiographic responses of liver metastases under therapy were investigated.METHODS: The cross-sectional sample consisted of 104 patients who were treated at the University Medical Center Hamburg-Eppendorf from 2008 to 2021 (mean age 62.3 ± 12.6 years, 58.7% male). GGT and liver imaging were identified in a time range of 3 months. Radiologic reassessments were performed to estimate liver tumor burden. In a separate longitudinal sample (n = 15), the course of GGT levels under chemotherapy was analyzed. Data were retrospectively analyzed with a univariate ANOVA, linear regression analyses, and Wilcoxon tests.RESULTS: Of 104 cross-sectionally analyzed patients, 54 (51.9%) showed a GGT elevation. GGT levels and liver tumor burden were positively correlated (p < 0.001), independently from age, gender, primary tumor location, grading, and cholestasis. Notably, GGT increase was associated with a liver tumor burden of >50%. In the longitudinal sample, 10 of 11 patients with progressive disease showed increasing GGT, whereas 4 of 4 patients with regressive disease showed declining GGT.CONCLUSION: Our findings indicate that GGT is associated with liver tumor burden. Over the course of therapy, GGT appears to change in line with radiographic responses. Further longitudinal studies with larger sample sizes are required to define GGT as a reliable marker for tumor response.",
author = "Schmidt, {Benjamin Christopher} and Leiderer, {Miriam Theresa} and Tania Amin and Fabrice Viol and Samuel Huber and Henes, {Frank Oliver} and J{\"o}rg Schrader",
note = "{\textcopyright} 2023. The Author(s).",
year = "2024",
month = feb,
doi = "10.1007/s12020-023-03545-x",
language = "English",
volume = "83",
pages = "511--518",
journal = "ENDOCRINE",
issn = "1355-008X",
publisher = "Humana Press",
number = "2",

}

RIS

TY - JOUR

T1 - Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?

AU - Schmidt, Benjamin Christopher

AU - Leiderer, Miriam Theresa

AU - Amin, Tania

AU - Viol, Fabrice

AU - Huber, Samuel

AU - Henes, Frank Oliver

AU - Schrader, Jörg

N1 - © 2023. The Author(s).

PY - 2024/2

Y1 - 2024/2

N2 - PURPOSE: In patients with neuroendocrine tumors (NETs) and liver metastases, increased gamma-glutamyltransferase (GGT) is commonly assumed as an indicator for progressive disease. To date, however, empirical data are lacking. This study aimed to investigate associations between GGT and liver tumor burden. In longitudinal analyses, associations of GGT and radiographic responses of liver metastases under therapy were investigated.METHODS: The cross-sectional sample consisted of 104 patients who were treated at the University Medical Center Hamburg-Eppendorf from 2008 to 2021 (mean age 62.3 ± 12.6 years, 58.7% male). GGT and liver imaging were identified in a time range of 3 months. Radiologic reassessments were performed to estimate liver tumor burden. In a separate longitudinal sample (n = 15), the course of GGT levels under chemotherapy was analyzed. Data were retrospectively analyzed with a univariate ANOVA, linear regression analyses, and Wilcoxon tests.RESULTS: Of 104 cross-sectionally analyzed patients, 54 (51.9%) showed a GGT elevation. GGT levels and liver tumor burden were positively correlated (p < 0.001), independently from age, gender, primary tumor location, grading, and cholestasis. Notably, GGT increase was associated with a liver tumor burden of >50%. In the longitudinal sample, 10 of 11 patients with progressive disease showed increasing GGT, whereas 4 of 4 patients with regressive disease showed declining GGT.CONCLUSION: Our findings indicate that GGT is associated with liver tumor burden. Over the course of therapy, GGT appears to change in line with radiographic responses. Further longitudinal studies with larger sample sizes are required to define GGT as a reliable marker for tumor response.

AB - PURPOSE: In patients with neuroendocrine tumors (NETs) and liver metastases, increased gamma-glutamyltransferase (GGT) is commonly assumed as an indicator for progressive disease. To date, however, empirical data are lacking. This study aimed to investigate associations between GGT and liver tumor burden. In longitudinal analyses, associations of GGT and radiographic responses of liver metastases under therapy were investigated.METHODS: The cross-sectional sample consisted of 104 patients who were treated at the University Medical Center Hamburg-Eppendorf from 2008 to 2021 (mean age 62.3 ± 12.6 years, 58.7% male). GGT and liver imaging were identified in a time range of 3 months. Radiologic reassessments were performed to estimate liver tumor burden. In a separate longitudinal sample (n = 15), the course of GGT levels under chemotherapy was analyzed. Data were retrospectively analyzed with a univariate ANOVA, linear regression analyses, and Wilcoxon tests.RESULTS: Of 104 cross-sectionally analyzed patients, 54 (51.9%) showed a GGT elevation. GGT levels and liver tumor burden were positively correlated (p < 0.001), independently from age, gender, primary tumor location, grading, and cholestasis. Notably, GGT increase was associated with a liver tumor burden of >50%. In the longitudinal sample, 10 of 11 patients with progressive disease showed increasing GGT, whereas 4 of 4 patients with regressive disease showed declining GGT.CONCLUSION: Our findings indicate that GGT is associated with liver tumor burden. Over the course of therapy, GGT appears to change in line with radiographic responses. Further longitudinal studies with larger sample sizes are required to define GGT as a reliable marker for tumor response.

U2 - 10.1007/s12020-023-03545-x

DO - 10.1007/s12020-023-03545-x

M3 - SCORING: Journal article

C2 - 37770647

VL - 83

SP - 511

EP - 518

JO - ENDOCRINE

JF - ENDOCRINE

SN - 1355-008X

IS - 2

ER -